The audio version of this article is generated by text-to-speech, a technology based on artificial intelligence.
A new deal with major drugmakers, unveiled by U.S. President Donald Trump on Thursday, aims to expand coverage and cut prices for popular weight-loss drugs south of the border.
The deal with Eli Lilly and Novo Nordisk is set to expand Medicare coverage of Zepbound and Wegovy, two GLP-1 receptor agonist medications . GLP-1 agonists — which include semaglutide medications such as Wegovy and Ozempic — are a class of medications that mimic the GLP-1 hormone to help treat diabetes and obesity.
Continue Reading on CBC News
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.